Erasca (ERAS) Could Be 40% Below Fair Value On Lawsuit And Trial Risk

Simply Wall St.06-26

Erasca (ERAS) is under pressure after a series of securities class action filings tied to its lead oncology candidate ERAS-0015, patent and trade secret allegations, and preliminary trial data that ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646719383?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-06-26 03:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646719383","market":"hk","top_or_hot":-1,"title":"Erasca (ERAS) Could Be 40% Below Fair Value On Lawsuit And Trial Risk","media":"Simply Wall St.","content":"<div>\n<p>Erasca (ERAS) is under pressure after a series of securities class action filings tied to its lead oncology candidate ERAS-0015, patent and trade secret allegations, and preliminary trial data that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/erasca-eras-could-be-40-below-fair-value-on-lawsuit-and-tria\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Erasca (ERAS) Could Be 40% Below Fair Value On Lawsuit And Trial Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nErasca (ERAS) Could Be 40% Below Fair Value On Lawsuit And Trial Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-26 03:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/erasca-eras-could-be-40-below-fair-value-on-lawsuit-and-tria><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Erasca (ERAS) is under pressure after a series of securities class action filings tied to its lead oncology candidate ERAS-0015, patent and trade secret allegations, and preliminary trial data that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/erasca-eras-could-be-40-below-fair-value-on-lawsuit-and-tria\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ERAS","symbol_name":"Erasca, INC.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/erasca-eras-could-be-40-below-fair-value-on-lawsuit-and-tria","article_id":"2646719383","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eras/erasca/news/erasca-eras-could-be-40-below-fair-value-on-lawsuit-and-tria","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2646719383","pubTimestamp":1782415231,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Erasca (ERAS) is under pressure after a series of securities class action filings tied to its lead oncology candidate ERAS-0015, patent and trade secret allegations, and preliminary trial data that included a reported patient death.\nSee our latest analysis for Erasca.\nErasca’s recent legal headlines came after a period of very strong momentum, with a year to date share price return of 319.22% and a very large 1 year total shareholder return. However, the 90 day share price return of 0.53%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ERAS":"Erasca, INC.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"Erasca(ERAS)的诉讼和审判风险可能比公允价值低40%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ERAS":1.5},"content_text":"Erasca (ERAS) is under pressure after a series of securities class action filings tied to its lead oncology candidate ERAS-0015, patent and trade secret allegations, and preliminary trial data that included a reported patient death. See our latest analysis for Erasca. Erasca’s recent legal headlines came after a period of very strong momentum, with a year to date share price return of 319.22% and a very large 1 year total shareholder return. However, the 90 day share price return of 0.53% points to fading short term strength. If this kind of volatility has your attention, it may be a good moment to broaden your watchlist with healthcare related AI opportunities using the 38 healthcare AI stocks. With Erasca shares up 319.22% year to date and trading at US$15.05, with an implied 39.53% gap to the US$21 analyst target, investors now face a simple question: is there real value left here, or is the market already pricing in future growth? AdvertisementPreferred Price-to-Book Multiple of 11.9x: Is It Justified? Erasca is attracting attention not just for its clinical news, but also for how the market is valuing the stock through its price-to-book ratio. The preferred metric available for Erasca is its price-to-book (P/B) ratio, which is 11.9x based on the latest data. This compares the company’s market value of equity to its book value of equity on the balance sheet, and is often used for early stage or loss making businesses where earnings based metrics like P/E are less useful. Relative to a peer group average P/B of 27.2x, Erasca screens as cheaper on this metric, which suggests investors are paying less for each dollar of book value than they are for those peers. However, when compared with the broader US Biotechs industry average P/B of 2.6x, Erasca is priced much higher, indicating that the stock carries a premium against the sector as a whole. This split picture, cheaper than selected peers but more expensive than the wider industry, leaves the P/B multiple in a middle ground rather than clearly pointing to a discount or an obvious premium that is out of line with its group. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book ratio of 11.9x (ABOUT RIGHT) However, Erasca’s securities class actions, patent and trade secret disputes, and reported trial patient death could still reshape expectations around its pipeline and valuation. Find out about the key risks to this Erasca narrative. Next Steps If this mix of legal risk, trial uncertainty and previous share price strength around Erasca leaves you unsure, take a closer look now and weigh both sides of the story with the 1 key reward and 4 important warning signs. Looking For More Investment Ideas Beyond Erasca? If Erasca has sharpened your focus on risk and reward, do not stop here. Broaden your opportunity set with other focused stock ideas using the Simply Wall St screener today.  Target potential mispricings by scanning a curated set of quality companies that look inexpensive relative to fundamentals using the 44 high quality undervalued stocks. Strengthen your portfolio’s foundations by searching for companies with robust finances using the solid balance sheet and fundamentals stocks screener (48 results). Hunt for underfollowed opportunities by checking a focused list of quality stocks that many investors may be ignoring through the screener containing 18 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Erasca might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646719383","isCrawlerRequest":true}